LENZ THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
LENZ THERAPEUTICS, INC. (LENZ) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $4.30 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-24.
Financial Statements › Notes
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-03-24
- LENZ THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2023-12-31 was $34.59K, a 75.13% decline year-over-year.
- LENZ THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2023-09-30 was $10.37K, a 39.02% decline year-over-year.
- LENZ THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2023-06-30 was $55.05K, a 25.26% increase year-over-year.
- LENZ THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2023-03-31 was $0.00.
- LENZ THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $4.30M, a 4.88% increase from fiscal 2024.
- LENZ THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $4.10M, a 4000.00% increase from fiscal 2023.
- LENZ THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $100.00K, a 50.00% decline from fiscal 2022.
- LENZ THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $200.00K, a 96.00% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|
| 2025-12-31 | $4.30M 10-K · filed 2026-03-24 | |||
| 2024-12-31 | $4.10M 10-K · filed 2026-03-24 | |||
| 2023-12-31 | $34.59K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $44.95K derived: sum of 2 quarters · filed 2024-02-27 | $100.00K derived: sum of 3 quarters · filed 2024-02-27 | $100.00K 10-K · filed 2024-02-27 |
| 2023-09-30 | $10.37K 10-Q · filed 2023-11-13 | $65.41K derived: sum of 2 quarters · filed 2024-02-27 | $65.41K 10-Q · filed 2023-11-13 | $204.47K derived: sum of 4 quarters · filed 2024-02-27 |
| 2023-06-30 | $55.05K derived: 10-K 12 month − 3 quarters · filed 2024-02-27 | $55.05K derived: sum of 2 quarters · filed 2024-02-27 | $194.10K derived: sum of 3 quarters · filed 2024-02-27 | $211.10K derived: sum of 4 quarters · filed 2024-02-27 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-11 | $139.06K derived: sum of 2 quarters · filed 2024-02-27 | $156.06K derived: sum of 3 quarters · filed 2024-02-27 | $200.00K derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-12-31 | $139.06K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $156.06K derived: sum of 2 quarters · filed 2024-02-27 | $200.00K derived: sum of 3 quarters · filed 2024-02-27 | $200.00K 10-K · filed 2024-02-27 |
| 2022-09-30 | $17.00K 10-Q · filed 2022-11-09 | $60.95K derived: sum of 2 quarters · filed 2022-11-09 | $60.95K 10-Q · filed 2022-11-09 | $360.94K derived: sum of 4 quarters · filed 2023-05-11 |
| 2022-06-30 | $43.95K 10-Q · filed 2022-08-11 | $43.95K 10-Q · filed 2022-08-11 | $343.94K derived: sum of 3 quarters · filed 2023-05-11 | $343.94K derived: sum of 4 quarters · filed 2023-05-11 |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-11 | $300.00K derived: sum of 2 quarters · filed 2023-05-11 | $300.00K derived: sum of 3 quarters · filed 2023-05-11 | $306.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | $300.00K derived: sum of 2 quarters · filed 2023-03-20 | $306.00K derived: sum of 3 quarters · filed 2023-03-20 | $5.00M 10-K · filed 2023-03-20 |
| 2021-09-30 | $0.00 10-Q · filed 2021-11-10 | $6.00K derived: sum of 2 quarters · filed 2021-11-10 | $4.70M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $6.00K 10-Q · filed 2021-08-12 | $4.60M 10-Q · filed 2021-08-12 | ||
| 2020-12-31 | $2.80M 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |